Skip to main content
Equibles
THC logo

THC · Tenet Healthcare Corp · Metrics

Track THC — free

Use THC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research THC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$268.95 +0.50 (+0.19%) At close · Oct 26
S&P 400 member Russell 1000 member Rebalance outlook locked
Customer concentration — key customers 69% of revenue

Key customers — 69% of revenue (the year ended December 31, 2025)

“our top 10 managed care payers generated 69% of our managed care net patient service revenues for the year ended December 31, 2025.”

Key customers — 67% of receivables (At December 31, 2025)

“At December 31, 2025, 67% of our Hospital Operations segment's net accounts receivable was due from managed care payers.”
View the 10-K filed Feb 17, 2026
Market Cap
$21.99B
Shares
80.52M
Volume · Oct 26 652.31K Avg daily vol (3M) 779.96K

THC metrics

107 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$268.95
Market cap
$21.99B

Price action

20 metrics
Price change (1W)
+1.0%
Price change (30D)
+4.3%
Price change (3M)
+10.5%
Price change (6M)
+45.0%
Price change (YTD)
+35.3%
Price change (1Y)
+27.8%
Trailing year
Price change (5Y)
+293.7%
52-week high
$280.77
52-week low
$161.37
Change from 52-week high
-4.2%
Change from 52-week low
+66.7%
Annualized volatility
43.3%
Annualized volatility (3M)
30.8%
Beta
0.5
RSI (14D)
54.9
Price vs SMA 50
+1.5%
Price vs SMA 200
+22.9%
Avg volume (3M)
779,963
Relative volume
0.8
Average dollar volume
$204.63M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
80.52M

Valuation

12 metrics
P / E (TTM)
10.4
Trailing earnings · reciprocal yield 9.6%
PEG ratio
0.0
EV / revenue
1.5×
reciprocal yield 66.0%
EV / EBITDA
6.1×
reciprocal yield 16.4%
EV / EBIT
7.3×
reciprocal yield 13.7%
P / sales
1.0×
reciprocal yield 99.2%
P / book
4.7
reciprocal yield 21.2%
FCF yield
13.7%
TTM · current market cap
Buyback yield
7.5%
P / FCF
7.3
reciprocal yield 13.7%
P / operating cash flow
5.5
reciprocal yield 18.3%
Earnings yield
14.4%

Historical valuation

8 metrics
P / E historical average (3Y)
9.9×
reciprocal yield 10.1%
P / E historical average (5Y)
10.7×
reciprocal yield 9.4%
EV / revenue historical average (3Y)
1.2×
reciprocal yield 84.5%
EV / revenue historical average (5Y)
1.1×
reciprocal yield 87.8%
EV / EBIT historical average (3Y)
6.7×
reciprocal yield 14.9%
EV / EBIT historical average (5Y)
7.1×
reciprocal yield 14.0%
EV / EBITDA historical average (3Y)
5.4×
reciprocal yield 18.7%
EV / EBITDA historical average (5Y)
5.6×
reciprocal yield 18.0%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
7.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-07-24

Profitability

9 metrics
Gross margin
—
Operating margin
20.8%
Trailing 12 months
Net margin
14.6%
Gross profit (TTM)
—
Operating profit (TTM)
$4.54B
Net income (TTM)
$3.17B
Trailing 12 months
Diluted EPS (TTM)
$25.93
FCF margin
13.9%
Effective tax rate
17.9%

Per share

11 metrics
Revenue per diluted share (TTM)
$250.80
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$52.40
EBITDA per diluted share (TTM)
$62.66
Net income per diluted share (TTM)
$36.64
Operating cash flow per diluted share (TTM)
$45.95
Free cash flow per diluted share (TTM)
$34.60
Capital expenditures per diluted share (TTM)
$11.35
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$1.52
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+6.8%
Year over year
Net income growth YoY
+100.2%
Revenue (TTM)
$21.81B
Trailing 12 months
EPS growth YoY
+213.4%
Shares change YoY
-8.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+3.6%
Revenue CAGR (5Y)
+3.9%
EPS CAGR (3Y)
+59.9%
EPS CAGR (5Y)
+32.8%
FCF CAGR (3Y)
+99.0%
FCF CAGR (5Y)
-2.5%

Quality

14 metrics
Return on equity
68.1%
Return on assets
10.3%
Debt / equity
2.8
Current ratio
1.4
EBITDA (TTM)
$5.43B
Free cash flow (TTM)
$3.02B
Quick ratio
1.3
Interest coverage
5.5
Net debt / EBITDA
2.0
Return on invested capital
23.7%
Trailing 12 months
Net cash
−$11.08B
Latest balance sheet
Cash & equivalents
$2.17B
Total assets
$30.68B
Total debt
$13.25B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.01B
Capital expenditures (TTM)
$992.00M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$132.00M
R&D / revenue
—
Stock compensation / revenue
0.6%

Ownership (13F)

9 metrics
13F filers
691
13F filer change QoQ
-14
Institutional ownership
102.0%
Conviction holders (share of 13F filers)
1.2%
Crowding (high-turnover and private-fund holders)
36.1%
Private-fund adviser ownership
35.0%
Active holders' share change QoQ
-3.7%
Holder tenure
17.4
Price vs estimated holder cost
+14.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
23.6%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 3.3 days to cover
Days to cover
3.3d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$45.18M
Insider-sentiment score
4 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 70318 CUSIP 88033G407 13F (30d) 177 filings 172 filers Visit website Investor relations